DESIRE
Development & Epilepsy

Strategies for Innovative Research to Improve Diagnosis, Prevention and Treatment In Children with Difficult to Treat Epilepsy

www.epilepsydesireproject.eu

COOPERATION

Call Identifier: F7-health-2013-Innovation-1
Project ID: Health-F2-602531-2013
Date of the EC Grant Agreement Signature: 22 July 2013
Start date: 1 October 2013
End date:September 2018
Duration: 60 Months
Total Project cost: €16,957,461.09
Total Project EC Funding: €11,995,646.00

What is DESIRE?

DESIRE is an FP7 funded project involving 25 partners in 11 countries, with more than 250 researchers and 19 centres involved in the clinical trial. It is co-ordinated by Prof. Renzo Guerrini, Dipartimento di Neuroscienze, Area del Farmaco e Salute del Bambino (NEUROFARBA) Universita degli Studi di Firenze, Italy.

What will DESIRE focus on?

DESIRE will focus on epileptogenic developmental disorders (EDD), i.e. early onset epilepsies whose origin is closely related to developmental brain processes.



A major cause of EDD are malformations of cortical development (MCD), either macroscopic or subtle. EDD are often manifested as epileptic encephalopathies (EE), i.e. conditions in which epileptic activity itself may contribute to severe cognitive and behavioral impairments. EDD are the most frequent drug-resistant pediatric epilepsies carrying a lifelong perspective of disability and reduced quality of life. Although EDD collectively represent a major medical and socio-economic burden, their molecular diagnosis, pathogenic mechanisms (PM) and rationale treatment are poorly understood.

What are the objectives of DESIRE?

The workplan is organised in a series of workpackages (WPs) which span from clinical observation, to whole exome studies, cellular and animal models and basic research, identification of biomarkers and improvement of diagnostic methods, and back to the clinical trials and assessment of innovative, targeted treatment strategies.

The objectives of DESIRE are to advance the state of the art with respect to:

- **the genetic and epigenetic causes of EDD, to elucidate molecular networks and disrupted protein complexes and search for common bases disorders.**
- **the diagnostic tools (biomarkers) through the study of a unique and well-characterized cohort of children to provide standardized diagnosis for patient stratification and research across Europe.**
- **treatment of EDD using randomized, multidisciplinary clinical protocols and testing in experimental models to address novel preventative strategies.**



Who are we?

P1 - Universita Degli Studi Di Firenze(Co-Ordinator) P2 - Fondazione Irccs Istituto Neurologico Carlo Besta P3 - Institut National De La Sante Et De La Recherche Medicale (Inserm) P4 - Universitaetsklinikum Erlangen P5 - Universita Degli Studi Di Verona P6 - Centre National De La Recherche Scientifique P7 - Istituto Italiano Di Tecnologia P8 - Agencia Estatal Consejo Superior De Investigaciones Cientificas P9 - King's College London P10 - Charite – Universitaetsmedizin Berlin P11 - Klinikum Der Universitaet Zu Koeln P12 - University College London P13- The University Of Liverpool P14 - Universite Libre De Bruxelles P15 - Christian-Albrechts-Universitaet Zu Kiel P16 - Baker Idi Heart And Diabetes Institute Holdings Limited P17 - Universita Ta Malta P18 - Di.V.A.L. Toscana Srl P19 - Micromed S.P.A. P20 - Varionostic Gmbh P21 - Cegat Gmbh P22 - Amarna Therapeutics Bv P23 - Cf Consulting Finanziamenti Unione Europea Srl P24 Universita Cattolica Del Sacro Cuore P25 - Ospedale Pediatrico Bambino Gesu

Do you want more info?

DESIRE project coordinator: Prof Renzo Guerrini, Dipartimento di Neuroscienze, Universita degli Studi di Firenze, Italy renzo.guerrini@unifi.it
WP Dissemination and Exploitation: Prof Janet Mifsud Department of Clinical Pharmacology and Therapeutics, University of Malta janet.mifsud@um.edu.mt